Novo's Ozempic gains MACE risk reduction label in US

Novo Nordisk’s Ozempic (semaglutide) weekly GLP-1 injection has gained a new US indication after the FDA agreed a label extension to cover reducing the risk of cardiac events in adults with

Novo Nordisk joins with UVA in diabetes digital simulation p...

Novo Nordisk has joined with the University of Virginia (UVA), in a five-year research collaboration where they will work together on developing virtual environments focused on digital simu

Novartis top of pile in European pharma in 2020, say Jefferi...

Jefferies’ team of analysts have recently been touting Roche as their favourite big European pharma – but going into 2020 it’s Novartis that gets the strongest “buy” rating in a broker note

Novo bolsters R&D pipeline with RNAi therapies from Dicerna

Novo Nordisk has further bolstered its liver disease R&D pipeline, signing a deal with US biotech Dicerna to discover and develop RNA-blocking therapies for diseases such as NASH and ty

Novo Nordisk buys rights to NASH drug from Japan's UBE

Novo Nordisk has acquired rights to a preclinical drug that could be used to treat non-alcoholic steatohepatitis (NASH), the fatty liver disease that could generate billions of dollars for

Novo Nordisk builds in haemophilia with Bluebird Bio gene ed...